Notice of NCATS Participation in RFA-HL-19-018 NHLBI SBIR Phase IIB Small Market Awards to Accelerate the Commercialization of Technologies for Heart, Lung, Blood, and Sleep Disorders and Diseases (R44 - Clinical Trial Optional)

Notice Number: NOT-TR-18-026/span>

Key Dates
Release Date: May 16, 2018

Related Announcements
RFA-HL-19-018

Issued by
National Center for Advancing Translational Sciences (NCATS)

Purpose

The purpose of this Notice is to inform potential applicants that the National Center for Translational Sciences (NCATS) will participate in RFA-HL-19-018 "NHLBI SBIR Phase IIB Small Market Awards to Accelerate the Commercialization of Technologies for Heart, Lung, Blood, and Sleep Disorders and Diseases (R44 - Clinical Trial Optional)".

Part 1. Overview Information

 
The following information has been added:

Components of Participating Organizations:
National Center for Advancing Translational Sciences (NCATS)

Catalog of Federal Domestic Assistance (CFDA) Number(s):
93.350

Part 2. Section II. Award Information

The following information has been added:

Funds Available and Anticipated Number of Awards
NCATS intends to commit total costs of $500,000 per year for the five-year duration of the program.

Inquiries

Please direct all inquiries to:

Lili Portilla, MPA
National Center for Advancing Translational Sciences (NCATS)
Telephone: 301-827-7170
Email: lilip@nih.gov